Bellicum Pharma $BLCM said that the preliminary results in the ongoing Phase 1/2 study of a lead candidate intended for patients suffering from blood cancer showed positive results. The drug-maker said that 18 subjects in a Phase 1/2 clinical trial evaluating lead product candidate BPX-501 in pediatric patients with acute leukemias showed all subjects remained disease-free at a median of 13 months of follow-up with no treatment-related mortality after a T-depleted haploidentical hematopoietic stem cell transplant (HSCT) and infusion of BPX-501. The outcome was presented at the 2016 Biennial Meeting of the European Society for Immunodeficiencies in Barcelona.

Marinus Pharmaceutical $MRNS shares vaulted on Friday as investors’ sentiment turned positive after the drug-maker said that it increased the target enrolment in Phase 2 trial for its lead candidate, ganaxoline. It is intended to cure female children with rare genetic epilepsies, including those with a mutation called PCDH19, characterized by early onset seizures. The original target enrolment was 20; however, it is now at 50. Drug-makers, typically, raise the target enrollments when the current numbers of subjects are insufficient to prove a treatment’s efficacy. Earlier in June, shares nosedived on the news that ganaxolone failed a late-stage clinical trial in adults with drug-resistant focal onset seizures. It also flunked a mid-stage study in children with Fragile X syndrome.

JNJ’s Mid-Stage Study on Treating HCV Demonstrates 100% Cure-Rate after 6-weeks of Treatment- Janssen Biotech’s $JNJ said that preliminary results from mid-stage clinical trial of triple combination HVC regimen showed strong results. The interim data from Phase 2a study demonstrated that the triple combination regimen, intended to cure patients with hepatitis C virus (HCV) genotype 1 infection, had 100% cure-rate, after only six weeks of treatment. The outcome of the study was presented on Friday at the European Association for the study of the Liver Special Conference in Paris. The drug-maker on Friday also submitted Biologics License Application (BLA) to the FDA seeking approval of treatment, sirukumab, intended for adult patients having moderate to severely active rheumatoid arthritis (RA), a chronic systemic inflammatory condition affecting nearly 1.5 million Americans.

Novartis’s Lead Lung Cancer Candidate Shows Good Results in Phase 3- Novartis AG $NVS said its lead lung cancer candidate Zykadia showed good results in Phase 3 study. The company now hopes that the results would help it expand regulatory approvals. Nonetheless, it faces a stiff competition from rival Roche, which some analysts say has better treatment intended for the disease. The Swiss pharmaceutical company presented the results of Phase 3 clinical study of Zykadia or ceritinib, on previously untreated patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients when treated with Zykadia showed a substantial progress in their chances of surviving without the cancer spreading compared with standard chemotherapy.

Medivir’s Mid-Stage Study of Arthritis Candidate MIV-711 to Go Ahead as Planned -Medivir AB $MVRBF said on Friday that its Phase 2a program for the treatment of Osteoarthritis would continue as planned after the Independent Data Monitoring Committee (DMC) recommended continuation of the study based on a review of unblended safety data. The first patient got enrolled into an open label phase 2a extension study, MIV-711-202. The aim of the study is to assess the clinical efficacy of the treatment for six months on patients with moderate knee osteoarthritis. The topline data of the study is expected in the second half of the next year and the outcome of the extension phase is anticipated in the first half of 2018.

AbbVie’s Viekirax + Exviera Shows High Clinical Efficacy- AbbVie Inc. $ABBV said results of Phase 3 clinical trial, GARNET, evaluating VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) in untreated patients with genotype 1b chronic hepatitis C virus (HCV) infection without cirrhosis showed a cure rate of 98% (n=160/163), 12 weeks after treatment (SVR12). The outcome was presented on Friday at the 2016 EASL Special Conference: New Perspectives in Hepatitis C Virus Infection - The Roadmap for Cure in Paris.

Novo Nordisk Submits Supplemental NDA to the FDA- Novo Nordisk $NVO submitted a supplemental Drug Application (sNDA) to the FDA seeking approval allowing the drug-maker to include results from two late-stage trials to to the label of long-acting insulin Tresiba (insulin degludec injection).

FDA, as expected, approved Amgen’s $AMGN Amjevita. The treatment would compete against AbbVie’s $ABBV Humira. With this approval, the regulatory agency okayed fourth drug intended to treat multiple inflammatory diseases such as moderately to severely active rheumatoid arthritis; active psoriatic arthritis; active ankylosing spondylitis (an arthritis that affects the spine);moderately to severely active Crohn’s disease; moderately to severely active ulcerative colitis; and moderate to severe plaque psoriasis.

The FDA on Friday approved the Switzerland-based multinational pharmaceutical, Novartis’ $NVS treatment, Ilaris, for its expanded use. The drug, which is intended to cure Cryopyrin-Associated Periodic Syndromes (CAPS), a Periodic Fever Syndrome condition, and Systemic Juvenile Idiopathic Arthritis (SJIA), an autoinflammatory disorder, got three simultaneous approvals for treating Tumor Necrosis Factor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF).

The USPTO Patent Trial and Appeals Board (PTAB) upheld five of Mallinckrodt’s (NYSE: MNK) patents of INOMAX (nitric oxide) gas for inhalation. The patents, which are valid till 2013, got challenged by Praxir Distribution (NYSE: PX). INOMAK has FDA’s approval. It improves oxygenation and lowers the need for extracorporeal membrane oxygenation in term and near-term (at least 34 weeks gestation) neonates with hypoxic respiratory failure linked with pulmonary hypertension in conjunction with ventilator support and other agents.

Shares of BioLine Rx LTD $BLRX surged on Friday amid high volume trading after it announced that it has inked an exclusive worldwide in-licensing agreement with BGN Technologies and Hadasit for a novel treatment intended for liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH). This new treatment BL-1220, is the second project in-licensed under the framework of the Company's strategic partnership with Novartis Pharma AG for the screening and development of novel drug candidates.

The clinical-stage pharmaceutical company, Catabasis Pharmaceuticals, $CATB, announced public offering of 2,500,000 shares of its common stock at a price of $4 a share. The gross proceeds from the secondary offering, before deducting the underwriter’s commission and discounts and other expected expenses, would amount to $10mn. The company granted the underwriter a 30-day option to buy additional 375,000 shares of common stock. CATB intends to utilize part these funds towards clinical trial costs (both ongoing and future) of its candidate edasalonexent (CAT-1004), while the remaining would be used for R&D expenses of other pipeline preclinical candidates, working capital, and general corporate expenses. The offering is scheduled to close on 28th September 2016.

Apricus Biosciences Inc. $APRI announced public offering of 13.1mn shares at $0.35 a share. For each share purchased, investors will get one five-year warrant to buy 3/4 of a share of stock at $0.45. Net proceeds will be utilized partly as working capital and for general corporate purposes. The San Diego California based company mainly focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. Shares tumbled in premarket hours though.

Paul Campanelli got appointed as President and CEO of Endo International Plc $ENDP with an immediate effect on Friday. He was serving as President of Endo’s generic and OTC drugs business, Par Pharmaceutical, a unit which generated about 60% of Endo’s total revenue through the first half of 2016. He joined Endo in 2015 after Endo acquired Par, where he served as CEO since 2012.